SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OXIGENE INC. (OXGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (205)6/2/2001 12:54:00 PM
From: scaram(o)uche  Read Replies (1) of 273
 
>> The comparison certainly leads one to conclude that the market has made a big mistake, to date, in valuing
combretastatin. <<

I'm finished with the mild nausea that swept over me after seeing the GLIA comparison, and can now state "not really!"

Let's not forget OXGN's heritage, Sensamide and Neu-Sensamide. If ever there was a bait and switch company, some might consider that Oxigene was it. Profit from keeping head up, and comparing apples with apples?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News